Metagenomi Therapeutics, Inc.
MGX
$1.46
-$0.02-1.35%
NASDAQ
Corporate Info
Website
Phone Number
510 871 4880
Address
5959 Horton Street
7th Floor
Emeryville, CA 94608
7th Floor
Emeryville, CA 94608
Country
United States
Year Founded
2016
Details
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Employees
124
Business Description
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company’s lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.